Novo Nordisk's future in doubt after Wegovy maker's 'surprise' CEO ouster
Novo Nordisk's ousting of longtime CEO Lars Fruergaard Jørgensen bemused analysts, with many questioning the future of the Wegovy obesity drug maker.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Novo
since
auto-detected in 650 stories
14 days ago
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and navigate other challenges
17 days ago
Novo Nordisk CEO to step down as Wegovy maker faces growing competition
The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post "for a period to support a smooth transition to new leadership."
Novo Nordisk chief Jørgensen to step down
Danish maker of obesity drugs says that new leadership is needed
26 days ago
Novo Nordisk cuts forecasts after replica obesity drugs hit US take-up
‘Compounded’ drugs custom made by pharmacies appeared after US regulator declared shortages in 2022
27 days ago
Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
34 days ago
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 18%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 18%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.